Abstract
We thank de Dios for their comments related to the differences in outcomes noted between our observations and previously published work exploring the role of ivabradine in patients with heart failure with preserved ejection fraction (HFpEF).1
We acknowledge the central issue: namely, the heterogeneity of patients recruited related to the lack of clear consensus regarding the pathophysiology of HFpEF and the inability of traditional diagnostic techniques, such as resting echocardiography, to diagnose this condition.
We acknowledge the central issue: namely, the heterogeneity of patients recruited related to the lack of clear consensus regarding the pathophysiology of HFpEF and the inability of traditional diagnostic techniques, such as resting echocardiography, to diagnose this condition.
Original language | English |
---|---|
Pages (from-to) | e604 |
Journal | Circulation |
Volume | 133 |
Issue number | 16 |
DOIs | |
Publication status | Published - 19 Apr 2016 |